Device Trial Radar · NCT07844317
Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
May 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Digital Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Assessment of an autonomous AI system for diabetic retinopathy detection in adults with diabetes using retinal imaging.
Conditions
- Diabetic Retinopathy (DR)
Interventions
SaMD intended for the detection of diabetic retinopathy in adults with diabetes.Device
No significant difference to other SaMDs for the detection of DR that are commercialized.
An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.Device
SaMD to detect diabetic retinopathy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the safety and efficacy of an AI-based SaMD with a fundus camera for the detection of Diabetic RetinopathyTime frame: 1-year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rovia Site Network
Jacksonville, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.